RESCINDED: FDA yanks Amarin ANCHOR SPA; shares tumble
This article was originally published in Scrip
Executive Summary
Shares of Amarin fell 16% in after-hours trading on 29 October after it revealed the US FDA has rescinded the special protocol assessment (SPA) agreement for the company's placebo-controlled Phase III ANCHOR study of Vascepa (icosapent ethyl) – making it even more unlikely the firm will win an expanded indication for the fish oil pill.
You may also be interested in...
'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins
Cardiovascular outcomes data exceeded expectations for the fish oil pill, vindicating Amarin, which has fought long and hard for Vascepa's place in the CV disease prevention market. A filing based on REDUCE-IT is expected in early 2019.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.